Moderna, Inc. and Catalent announce a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate (mRNA-1273) at Catalent’s biologics facility in Bloomington, Indiana. 

Catalent Biologics signs agreement with AstraZeneca to manufacture its vaccine candidate. It will provide vial filling and packaging capacity at Catalent’s manufacturing facility in Anagni, Italy, and prepare for large-scale commercial supply of the University of Oxford’s adenovirus vector-based COVID-19 vaccine candidate, AZD1222.

In his role at Catalent, Dejan specializes in the material science of excipients, specifically fillers and polymers for immediate and controlled release solid dosage forms. His strong expertise in particle engineering and compaction process includes tableting and dry granulation. Discover what drives Dejan’s passion for pharmaceutical materials science. Access his published works, including a patent and peer-reviewed articles.

BIOLOGICS

‌

• Webinar: “ASCO Postview: Highlights from the 2020 Virtual Conference” - Experts break down the data released during the recent American Society of Clinical Oncology (ASCO) virtual conference, as well as the implications they could have for prescribers, patients and drug makers.
• Executive Summary: “Radiance® Label-Free Monitoring of AAV Transfection in HEK293 Cells Using Laser Force Cytology™” - Catalent and LumaCyte experts collaborate to compare AAV production with three different transfection reagents using both LumaCyte’s Laser Force Cytology (LFC) instrument, Radiance®, and a digital droplet polymerase chain reaction (ddPCR) based viral genome titer assay.
• Webinar: “Cancer R&D Summit: The Outlook for Cancer Gene Therapies” - What hurdles need to be overcome before gene therapy is a major new modality in the cancer therapy arsenal? Catalent’s Thomas VanCott, Ph.D., and other industry experts discuss manufacturing, viral vectors, and consider the most promising approaches employed in new treatments coming to the clinic.
• Webinar: “R&D Leadership During the Pandemic” - Top R&D execs discuss how they’ve reorganized global teams, tapped new programs as a priority to fight COVID-19 and plan for the future after the pandemic has passed. View this fireside chat with Endpoints Founder John Carroll and Laurie H. Glimcher, President and CEO of the Dana-Farber Cancer Institute followed by a panel discussion from leaders at GlaxoSmithKline, Takeda, Amgen, Johnson & Johnson and Catalent’s Chair & CEO John Chiminski.

CLINICAL SUPPLY SERVICES

‌

• Article: “Finding New Efficiencies in Clinical Trial Logistics” - The COVID-19 pandemic has led to increased demand for direct-to-patient shipments, challenging cold-chain specialists to become more agile and to strengthen their global distribution networks. Eric Valentine, Vice President of Clinical Supply Services recently joined other industry experts in sharing his insights with Pharmaceutical Technology.
• Article: “APAC Region Distribution Considerations for Clinical Trial Supplies” - Maintaining business continuity when executing a supply chain plan is critical to a trial’s success. Catalent’s Daniel Gao and Tracey Clare address common distribution challenges encountered within APAC and discuss possible solutions a sponsor should consider and implement.
• Webinar: “How Protocol Design Drives Comparator Sourcing Cost, Timelines, Complexity and Risk” - Clinical trial protocol design can have a significant impact on commercial drug sourcing strategy. Learn the appropriate level of detail to include in the study protocol to help avoid common sourcing issues.

ORAL DRUG DELIVERY

‌

• Article: “Formulating for Convenience and Compliance” - In this month’s issue of Pharmaceutical Technology, Ralph Gosden, Head of Product Development at Catalent’s facility in Swindon, U.K., describes the benefits of orally disintegrating tablets (ODTs) and explains how they can improve patients’ experiences.
• ebook: “Elemental Impurities- Guidelines, Testing and Assessments” - Published by Pharmaceutical Technology, this eBook provides an overview of the regulatory landscape related to elemental impurities testing, discusses the challenges of implementing ICH Q3D guidelines, and describes strategies for compliance.
• Webinar: “How to Effectively Work with a Development Partner – From a Consultant Standpoint” – Efficient drug development requires that scientific, business and regulatory activities are integrated. Hear from industry experts on the latest tips that will help your clients avoid critical pitfalls in early drug development. Hear case studies in characterization and formulation of oral small molecule drugs presented, which can help your clients succeed.

CONSUMER HEALTH

‌

• ebook: “Active Aging - Opportunities to Support Health-Minded Consumers with Improved Nutritional Supplements” - Learn about the move to focus on ‘health’ rather than ‘years’, and gain nutritional insights that can help support being active across a wide range of activities.
• Infographic: “Innovation in OTC Products – A Survey Report on Why It Matters and How to Achieve It” - Catalent and FiercePharma conducted a survey which generated responses from the OTC industry. Download this infographic to learn more about survey results and expert insight on trends uncovered by the survey.
• Webinar: “The Rise of Beauty Nutrition” - The conventional beauty industry is focused on aesthetics, while the nutritional industry focuses on wellbeing. As these massive markets overlap, there is an opportunity for a broader range of solutions, products, and technologies to meet consumer expectations and advantages of combining these two perspectives.

At Catalent, you will have the opportunity to thrive in a fast-paced, innovative environment where maximizing your potential isn’t just your own personal goal, it’s ours too.

‌

We are rapidly growing in multiple locations including Bloomington, Madison, St. Petersburg & at our Gene Therapy sites in Maryland. 

‌